TerminatedNot applicableNCT00852644

Stereotactic Radiosurgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer

RATIONALE: Stereotactic radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I trial is studying the side effects and best dose of stereotactic radiosurgery in treating patients with stage I or stage II non-small cell lung cancer.

Checked against the public recordLast updated May 11, 2018 · Source: ClinicalTrials.gov

StatusTerminated
PhaseNot applicable
U.S. locations1
SponsorBoston Medical Center
01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Not applicable
Sponsor
Boston Medical Center
Interventions being studied
Procedure: computed tomography; Radiation: fludeoxyglucose F 18; Radiation: hypofractionated radiation therapy; Radiation: stereotactic radiosurgery
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: DISEASE CHARACTERISTICS: * Histologically confirmed non-small cell lung cancer * Stage I or II disease (T1-3, N0, M0) * T2 or T3 tumor ≤ 5 cm * No T3 tumors involving the central chest or mediastinum (only chest wall involvement allowed) * Tumor deemed technically resectable, in the opinion of an experienced thoracic surgeon, AND patient deemed "medically inoperable" * Patients with fluorodeoxyglucose (FDG)-avidity in mediastinal lymph nodes are eligible provided they are able to undergo mediastinoscopy to confirm N0 status PATIENT CHARACTERISTICS: * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Not pregnant or nursing * Fertile patients must use effective contraception during and for ≥ 6 months after completion of study treatment Exclusion Criteria: * No history of contrast allergy * No psychological issues that would preclude the completion of study treatment PRIOR CONCURRENT THERAPY: * No prior radiotherapy or chemotherapy * No suspected nodal metastasis that cannot be falsified by mediastinoscopy (i.e., hilar or mediastinal nodes that are either fludeoxyglucose F 18 \[FDG\]-avid or measure \> 1 cm in short axis diameter on CT scan) * No tumor within or touching the proximal bronchial tree, defined as a volume of 2 cm in all directions around the proximal bronchial tree (carina, right and left main stem bronchi, right and left upper lobe bronchi, bronchus intermedius, right middle lobe bronchus, lingular bronchus, right and left lower lobe bronchi)

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Boston University Cancer Research CenterBoston, Massachusetts

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 11, 2018. Always confirm current availability with the study team.

View original record ↗